FibroGen

Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit
AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit
Fierce Pharma
FibroGen
trade secrets
anemia
Flag link:
After high-profile US rejection for roxadustat, Astellas touts its safety in new pooled analysis
After high-profile US rejection for roxadustat, Astellas touts its safety in new pooled analysis
Fierce Pharma
Astellas
roxadustat
FibroGen
ERA
erythropoietin
Flag link:
AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection
AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection
Fierce Pharma
AstraZeneca
FibroGen
chronic kidney disease
roxadustat
Flag link:
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
Fierce Pharma
FDA
drug approvals
FibroGen
AstraZeneca
daprodustat
Bristol Myers Squibb
Opdivo
Roche
tiragolumab
Merck
favezelima
bInnovent
Eli Lilly
Akeso Biopharma
Sino Biopharmaceutical
Novartis
Ukoniq
TG Therapeutics
GW Pharmaceuticals
Marinus Pharmaceuticals
Flag link:
The quest for efficacy in pancreatic cancer
The quest for efficacy in pancreatic cancer
EP Vantage
pancreatic cancer
Novartis
FibroGen
Tyme Technologies
Erytech
Rafeal Pharmaceuticals
Flag link:
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting
Fierce Pharma
FibroGen
AstraZeneca
anemia
roxadustat
FDA
Flag link:
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
Fierce Biotech
GSK
chronic kidney disease
cliincal trials
FDA
AstraZeneca
anemia
erythropoietin
FibroGen
Flag link:
FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data
FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data
Endpoints
FibroGen
roxadustat
cancer
anemia
clinical trials
data manipulation
Flag link:
After FDA snub, EMA backs FibroGen, Astellas’ roxadustat
After FDA snub, EMA backs FibroGen, Astellas’ roxadustat
Pharmaforum
Europe
FibroGen
Astellas
Evrenzo
anemia
chronic kidney disease
Flag link:
FDA declines to approve FibroGen's anemia drug
FDA declines to approve FibroGen's anemia drug
Yahoo/Reuters
FibroGen
FDA
anemia
chronic kidney disease
roxadustat
Flag link:
FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat
FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat
Seeking Alpha
FibroGen
FDA
roxadustat
advisory panels
chronic kidney disease
Flag link:
FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
Endpoints
FibroGen
anemia
roxadustat
Flag link:
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
Endpoints
FibroGen
roxadustat
FDA
advisory panel
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
Fierce Pharma
AstraZeneca
FibroGen
roxadustat
FDA
anemia
Flag link:
Astellas, FibroGen get approval in Japan for Evrenzo to treat anaemia of CKD in adult patients not on dialysis
Astellas, FibroGen get approval in Japan for Evrenzo to treat anaemia of CKD in adult patients not on dialysis
Pharmaceutical Business Review
Astellas
FibroGen
Japan
Evrenzo
chronic kidney disease
Flag link:
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
BioSpace
FibroGen
roxadustat
ASN
chronic kidney disease
Flag link:
5 FDA approval decisions to watch in the 4th quarter
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Flag link:

Pages